Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in
treating patients who have prostate cancer that has not responded to previous hormone
therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer
cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.